Methscopolamine Availability: What Providers and Prescribers Need to Know in 2026

Methscopolamine bromide is an anticholinergic antispasmodic that has occupied a niche role in GI therapeutics for decades. While it is not currently listed on the FDA Drug Shortage Database, providers who prescribe it are encountering a consistent challenge: patients are unable to fill prescriptions because pharmacies don't routinely stock the drug. This briefing summarizes the supply landscape, clinical context, and practical guidance for managing patients who need methscopolamine in 2026.

Current Supply Status

As of 2026, methscopolamine bromide is not on the FDA Drug Shortage Database. Generic tablets in 2.5 mg and 5 mg strengths are still being manufactured by a limited number of generic producers including Unichem Pharmaceuticals (USA), Inc. However, the drug's reduced prescribing volume means pharmacy-level inventory is thin and inconsistent.

The commercial brand Pamine has been discontinued, and there are no current manufacturer-sponsored savings programs. Compounding pharmacies remain a legitimate avenue for patients whose local retail pharmacies cannot source the generic.

Clinical Background: Why Prescribing Has Declined

Methscopolamine was widely used as adjunctive therapy for peptic ulcer disease before the discovery of H. pylori's role in ulcerogenesis and the subsequent development of PPIs and H2 receptor antagonists. The FDA notes in the prescribing information that methscopolamine "has not been shown to be effective in contributing to the healing of peptic ulcer, decreasing the rate of recurrence, or preventing complications."

Its role today is primarily symptomatic relief — reducing acid secretion volume and slowing GI motility to reduce pain and cramping. The AGS Beers Criteria (2019) advises avoiding anticholinergic agents like methscopolamine in older adults due to risks of cognitive impairment, urinary retention, constipation, and other anticholinergic adverse effects.

Mechanism of Action Summary

Methscopolamine is a quaternary ammonium muscarinic antagonist. As a quaternary compound, it does not cross the blood-brain barrier significantly, limiting CNS side effects compared to tertiary anticholinergics such as scopolamine. Its peripheral effects include:

Reduction in gastric acid volume and total acid content

Inhibition of GI motility

Inhibition of salivary secretion

Pupillary dilation and inhibition of accommodation

Inhibition of sweating (risk of hyperthermia in hot environments)

Dosing Reference

Standard adult dosing for peptic ulcer (adjunctive):

Initial: 2.5 mg PO 30 minutes before meals + 2.5–5 mg at bedtime (total 12.5 mg/day)

Severe symptoms: 5 mg PO 30 minutes before meals + 5 mg at bedtime (total 20 mg/day)

Maximum tolerated: 30 mg/day in some patients

Not approved for patients under 18 years of age

37,852+ patients found their medications in stock

37K+

Find Methscopolamine In Stock Today →

Contraindications to Review Before Prescribing

Screen patients for the following absolute contraindications before initiating methscopolamine:

Glaucoma (angle-closure or narrow-angle)

Obstructive uropathy or BPH with urinary retention

Myasthenia gravis

Paralytic ileus or intestinal atony (especially in elderly/debilitated patients)

Toxic megacolon or severe ulcerative colitis

Unstable cardiovascular status in acute hemorrhage

Key Drug Interactions for Prescribers

Methscopolamine carries multiple clinically significant interactions:

Pramlintide (Symlin): Contraindicated — synergistic inhibition of GI motility

Other anticholinergics: Additive anticholinergic toxicity (confusion, urinary retention, constipation, heat stroke risk)

Tricyclic antidepressants: Additive anticholinergic burden; monitor closely

Antipsychotics: Additive anticholinergic effects; methscopolamine may reduce absorption of some oral antipsychotics

Opioids / CNS depressants: Enhanced sedation; increased risk of constipation and urinary retention

Botulinum toxin products: Potentiates neuromuscular weakness and systemic anticholinergic effects

Aluminum hydroxide antacids: Reduces oral absorption of methscopolamine; administer separately

Skip the calls, skip the stress.

Find Methscopolamine In Stock Today →

50K+

Medications
Found

99%

Success
Rate

6+

Hours saved
on average

Therapeutic Alternatives by Clinical Goal

When methscopolamine is unavailable, the appropriate alternative depends on your clinical goal:

Acid suppression: PPIs (omeprazole, pantoprazole, lansoprazole) or H2 blockers (famotidine) are preferred and more effective for ulcer healing.

GI antispasmodic / motility reduction: Hyoscyamine (Levsin) or dicyclomine (Bentyl); glycopyrrolate (Robinul) is structurally similar to methscopolamine and may be appropriate for some patients.

How to Help Your Patients Find Methscopolamine

If you have patients who need methscopolamine and are having trouble filling it, directing them to medfinder can save them significant time. medfinder contacts local pharmacies to verify which ones have the drug in stock and can fill the prescription, then delivers results by text. For a low-volume drug like methscopolamine, this is far more efficient than patients calling pharmacies themselves.

You can also review our full provider guide: How to Help Your Patients Find Methscopolamine In Stock.